From biopsy to vaccine in two weeks: AI-mediated neoantigen selection and manufacturing for personalized cancer vaccines

“This is not conventional vaccine manufacturing… it depends on proximity to the hospitals and clinical teams involved in each patient’s care.”

Ashling Cannon, Editor, Vaccine Insights , speaks with Prasun Chakraborty, Founder, Innovator and CEO, Genevation LTD, about the rationale for a cell-free, lipid nanoparticle (LNP)-free personalized cancer vaccine platform. Chakraborty discusses preclinical dosing and durability data from melanoma and lung cancer mouse models, the AI-assisted approach used to select and validate neoantigen candidates, the manufacturing redundancy strategy built into sequence design, and the practical and political challenges of establishing a centralized, AI-mediated cancer vaccine manufacturing hub in the UK.

Please enter your email to access content Read now